Related Experiment Video
Updated: May 27, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Gastrointestinal stromal tumors
Alexander W Beham1, Inga-Marie Schaefer, Philipp Schüler
1Department of Surgery, University of Göttingen, Robert Koch Str. 42, 37075, Göttingen, Germany.
Introduction:
The gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the intestinal tract, known to be refractory to conventional chemotherapy or radiation. Its pathogenesis is defined by mutations within the KIT and PDGFRA gene, which constitutively activate KIT and PDGFRA oncoproteins, and serve as crucial diagnostic and therapeutic targets.
Discussion:
Besides surgery, therapy with imatinib mesylate, which inhibits KIT kinase activity, represents the other cornerstone for the treatment of GIST. Still, the only curative option for GIST is given after complete surgical removal even in a metastatic setting, but recurrence is common, and the risk can be defined by surgical factors like incomplete resection, intraperitoneal rupture, or bleeding and tumor associated factors like tumor size, mitotic index, or localization.
Conclusion:
Consequently, adjuvant therapy with imatinib mesylate or other tyrosine kinase inhibitors is recommended for high-risk patients after complete resection. For unresectable and advanced GIST, a partial response or stable disease can be achieved in about 80% of patients with imatinib mesylate.
Insights
Gastrointestinal stromal tumors (GIST) are common but resistant to traditional treatments. Imatinib mesylate is a key therapy, but surgery remains the only cure, with adjuvant therapy recommended for high-risk cases.
Area of Science:
- Gastrointestinal stromal tumors (GIST)
- Oncology
- Molecular targeted therapy
Background:
- GIST is the most common mesenchymal tumor of the intestinal tract.
- GIST is often refractory to conventional chemotherapy and radiation.
- Pathogenesis involves KIT and PDGFRA gene mutations, activating oncoproteins.
Purpose of the Study:
- To summarize the current understanding of GIST treatment.
- To highlight the role of imatinib mesylate in GIST therapy.
- To discuss factors influencing GIST recurrence and management strategies.
Main Methods:
- Review of existing literature on GIST pathogenesis and treatment.
- Analysis of therapeutic outcomes with imatinib mesylate.
- Identification of risk factors for GIST recurrence post-surgery.
Main Results:
- Imatinib mesylate inhibits KIT kinase activity and is a cornerstone therapy for GIST.
- Complete surgical removal is the only curative option, but recurrence is common.
- Adjuvant therapy with tyrosine kinase inhibitors is recommended for high-risk patients.
Conclusions:
- Imatinib mesylate offers significant response rates (around 80%) for unresectable and advanced GIST.
- Risk stratification for recurrence involves surgical and tumor-associated factors.
- Adjuvant imatinib mesylate is crucial for high-risk GIST patients post-resection.
